Literature DB >> 2462495

Effects of dopamine on immunoreactive growth hormone-releasing factor and somatostatin secretion from rat hypothalamic slices perifused in vitro.

N Kitajima1, K Chihara, H Abe, Y Okimura, Y Fujii, M Sato, S Shakutsui, M Watanabe, T Fujita.   

Abstract

The effects of dopamine (DA) on the release of GRF and somatostatin (SRIF) from the hypothalami of adult male rats were examined in an in vitro perifusion system using horizontal hypothalamic slices, 400 micron thick, including the median eminence and arcuate nuclei. When hypothalamic slices from five animals were perfused in a chamber with artificial cerebrospinal fluid (ACSF) at a flow rate of 100 microliters/min under a gaseous phase of 95% O2 and 5% CO2 at 37 C, rat (r) GRF- and SRIF-like immunoreactivities (-LI) were constantly detected in 30-min perifusates at least until 240 min of perifusion, and during the perifusion with 60 mM K+, the concentrations of rGRF-LI and SRIF-LI were increased 2.1 and 3.2 times, respectively, over basal values. Under the perifusion with ACSF containing normal goat gamma-globulin, the addition of 10(-8) M DA resulted in a significant increase in SRIF-LI from 8.2 +/- 0.3 to 14.3 +/- 1.5 pg/hypothalamus.30 min, but conversely, it caused a slight but significant decrease in rGRF-LI from 4.5 +/- 0.9 to 2.0 +/- 0.3 pg/hypothalamus.30 min. On the other hand, 10(-8) and 10(-6) M DA significantly stimulated rGRF-LI release from hypothalamic slices perifused with ACSF containing anti-SRIF goat gamma-globulin. These findings suggest that DA is a secretagogue for both SRIF and rGRF in the hypothalamus, but the rGRF-stimulating effect of DA is masked unless the action of endogenous SRIF is attenuated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462495     DOI: 10.1210/endo-124-1-69

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Reserpine-induced immunocytochemical change of neuropeptide Y in the hypothalamic arcuate nucleus.

Authors:  H Okamura; T Sugano; Y Ibata
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

2.  Early postnatal administration of growth hormone increases tuberoinfundibular dopaminergic neuron numbers in Ames dwarf mice.

Authors:  Christina E Khodr; Sara Clark; Alex F Bokov; Arlan Richardson; Randy Strong; David L Hurley; Carol J Phelps
Journal:  Endocrinology       Date:  2010-05-12       Impact factor: 4.736

3.  Does the dopamine transporter protein allele predict growth hormone testing results or response to growth hormone therapy?

Authors:  Maala Daniel; Lucy D Mastrandrea; Robbert J Salis; Richard Erbe; Teresa Quattrin
Journal:  Endocrine       Date:  2010-03-06       Impact factor: 3.633

4.  Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly.

Authors:  R Attanasio; P G Chiodini; A Liuzzi; P Orlandi; C De Palo; D Dallabonzana; A Lodrini; R Cozzi
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

Review 5.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  Central [CNS] and Peripheral [Gastric Tissue] Selective Monitoring of Somatostatin (SRIF) with Micro-Sensor and Voltammetry in Rats: Influence of Growth Factors (GH, EGF).

Authors:  Francesco Crespi
Journal:  Biosensors (Basel)       Date:  2017-11-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.